Sulpiride
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
- Sulpiride
- Sulpiride: From Antipsychotic Use to Retinal Dystrophy with or without Extraocular Anomalies
Sulpiride: From Antipsychotic Use to Retinal Dystrophy with or without Extraocular Anomalies
One-Sentence Summary
Sulpiride is a benzamide-class selective D2/D3 dopamine receptor antagonist, historically used as an antipsychotic; no formal original-indication or UK licensing data are recorded in this evidence pack. The TxGNN model predicts a possible link to retinal dystrophy with or without extraocular anomalies, a rare congenital/genetic eye disorder, but this is currently supported by 0 clinical trials and 15 tangentially related publications, none of which study Sulpiride directly. The evidence base is model-prediction only, with no biologically plausible mechanistic link identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in the evidence pack (no marketing authorisation or indication text on file). Known drug class: benzamide-class D2/D3 receptor antagonist, typically used as an antipsychotic |
| Predicted New Indication | Retinal dystrophy with or without extraocular anomalies |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for Sulpiride is not available in this evidence pack (flagged as a High-severity data gap). Based on the information that is available, Sulpiride is understood to be a selective D2/D3 dopamine receptor antagonist of the benzamide chemical class, conventionally used to manage psychotic disorders through central dopaminergic blockade.
Retinal dystrophy with or without extraocular anomalies is a congenital/genetic condition involving structural developmental abnormalities of the retina and, in some cases, the extraocular muscles — it is not a disorder driven by dopaminergic signalling. There is no established pharmacological or embryological pathway connecting D2/D3 receptor antagonism to the correction of inherited structural eye malformations.
On the evidence available, the biological plausibility of this prediction is low. The condition arises from developmental or genetic defects rather than a pharmacologically reversible pathological process, and no mechanistic rationale currently supports Sulpiride as an intervention. This assessment is consistent across the other TxGNN-ranked candidates for this drug (ranks 2–9 in the evidence pack), which include severe congenital brain and neuromuscular structural disorders (e.g. hydranencephaly, polymicrogyria with cerebellar hypoplasia, Charcot-Marie-Tooth disease type 1G) — none of which have any supporting clinical trial or literature evidence, suggesting the high TxGNN scores in this cluster may reflect graph-level prediction noise rather than genuine pharmacological signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Note: None of the publications identified specifically investigate Sulpiride in relation to this condition; they describe the clinical phenotype of extraocular/congenital eye anomalies in general terms and are included here as background disease-context literature only.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9416661 | 1997 | Review | Seminars in Ultrasound, CT, and MR | Overview of orbital infections and cellulitis staging; no drug relevance |
| 20127583 | 2010 | Review | Seminars in Neurology | Diagnostic approach to diplopia from ocular/neurologic/muscular causes |
| 22241537 | 2012 | Review | Klinische Monatsblätter für Augenheilkunde | Congenital ptosis with levator muscle dystrophy and fibrosis |
| 38249493 | 2023 | Review | Taiwan Journal of Ophthalmology | Congenital anomalies of lens shape and associated anterior segment dysgenesis |
| 7035111 | 1981 | Review | Documenta Ophthalmologica | Wagner-Stickler syndrome vitreoretinal degeneration with extraocular manifestations |
| 38321238 | 2024 | Review | Pediatric Radiology | Imaging classification of congenital/developmental pediatric ocular pathologies |
| 19064847 | 2008 | Review | Archives of Ophthalmology | Case series on orbital arteriovenous malformations |
| 109006 | 1979 | Case Report | American Journal of Ophthalmology | Unilateral cryptophthalmia with absent extraocular muscles and optic nerve |
| 24413161 | 2014 | Case Report | Journal of Neuro-Ophthalmology | Congenital trochlear-oculomotor synkinesis, a cranial dysinnervation disorder |
| 19826317 | 2009 | Case Report | Optometry and Vision Science | Congenital fibrosis of extraocular muscles with variable synergistic divergence |
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(Note: key warnings, contraindications, and drug interaction data are marked as a Blocking data gap in this evidence pack and have not yet been retrieved from a UK-approved product label.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- The TxGNN score is very high, but no clinical trials and no drug-specific literature support a link between Sulpiride and this rare congenital retinal/extraocular disorder; the available publications describe disease phenotype only, not Sulpiride treatment.
- The condition is structural/developmental in origin, and no mechanistic pathway connects D2/D3 receptor antagonism to correcting inherited eye malformations — biological plausibility is low. This same pattern (high score, zero supporting evidence, no mechanistic basis) recurs across the other TxGNN-ranked candidates for this drug (ranks 2–9), reinforcing that this prediction cluster is not yet actionable.
To proceed, the following is needed:
- Sulpiride’s original mechanism of action and approved indication data (currently a High-severity data gap)
- Product label warnings, contraindications, and drug interaction data (currently a Blocking data gap for safety triage)
- Any preclinical or mechanistic studies specifically linking dopaminergic modulation to retinal/extraocular structural development, if such studies exist
- Re-evaluation once UK marketing authorisation status and dosage form availability are confirmed
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.